RET germline mutation in codon 791 in a family representing 3 generations from age 5 to age 70 years: Should thyroidectomy be performed?

Endocrine Practice

Volumn 10, Issue 1, 2004, Pages 5-9

  Brauer, Volker F H ^a   Scholz, Gerhard H ^a   Neumann, Susanne ^a   Lohmann, Tobias ^b   Paschke, Ralf ^a   Koch, Christian A ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN RET; PROTEIN TYROSINE KINASE; RET PROTEIN, HUMAN;

ACROMEGALY; ADULT; AGED; ARTICLE; CHILD; CODON; FEMALE; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; HUMAN; MALE; MUTATION; PRESCHOOL CHILD; SIPPLE SYNDROME; THYROIDECTOMY;

ACROMEGALY; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CODON; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; MALE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROIDECTOMY;

EID: 3242882342     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.10.1.5     Document Type: Article

References (31)

1. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: international RET mutation consortium analysis. JAMA. 1996;276:1575-1579.
2. Gagel RF. Multiple Endocrine Neoplasia. 10th ed. Philadelphia, PA: WB Saunders, 2002: 1717-1762.
3. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658-5671.
4. Farndon JR, Leight GS, Dilley WG, et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg. 1986;73: 278-281.
5. Myers JH, Eversman JJ. Acromegaly, hyperparathyroidism, and pheochromocytoma in the same patient: a multiple endocrine disorder. Arch Intern Med. 1981;141: 1521-1522.
6. Miedlich S, Krohn K, Lamesch P, Muller A, Paschke R. Frequency of somatic MEN1 gene mutations in monoclonal parathyroid tumours of patients with primary hyperparathyroidism. Eur J Endocrinol. 2000;143:47-54.
7. Bolino A, Schuffenecker I, Luo Y, et al. RET mutations in exons 13 and 14 of FMTC patients. Oncogene. 1995;10:2415-2419.
8. Machens A, Gimm O, Hinze R, Hoppner W, Boehm BO, Dralle H. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab. 2001;86:1104-1109.
9. Fitze G, Schierz M, Bredow J, Saeger HD, Roesner D, Schackert HK. Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations. Ann Surg. 2002;236: 570-575.
10. Berndt I, Reuter M, Saller B, et al. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab. 1998;83:770-774.
11. Niccoli-Sire P, Murat A, Rohmer V, et al (French Calcitonin Tumors Group [GETC]). Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients. J Clin Endocrinol Metab. 2001;86:3746-3753.
12. Gimm O, Niederle BE, Weber T, et al. RET proto-oncogene mutations affecting codon 790/791: a mild form of multiple endocrine neoplasia type 2A syndrome [with discussion]? Surgery. 2002;132:952-959.
13. Lombardo F, Baudin E, Chiefari E, et al. Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804. J Clin Endocrinol Metab. 2002;87:1674-1680.
14. Gagel RF, Cote GJ, Martins Bugalho MJ, et al. Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A. J Intern Med. 1995;238: 333-341.
15. Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev. 2001;12: 361-373.
16. Huang SC, Koch CA, Vortmeyer AO, et al. Duplication of the mutant RET allele in trisomy 10 or loss of the wildtype allele in multiple endocrine neoplasia type 2-associated pheochromocytomas. Cancer Res. 2000;60:6223-6226.
17. Huang SC, Torres-Cruz J, Pack SD, et al. Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:459-463.
18. Koch CA, Huang SC, Moley JF, et al. Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma. Oncogene. 2001;20: 7809-7811.
19. Koch CA, Pacak K, Chrousos GP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab. 2002; 87:5367-5384.
20. Marsh DJ, Learoyd DL, Andrew SD, et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf). 1996;44:249-257.
21. Landsvater RM, de Wit MJ, Zewald RA, et al. Somatic mutations of the RET proto-oncogene are not required for tumor development in multiple endocrine neoplasia type 2 (MEN 2) gene carriers. Cancer Res. 1996;56:4853-4855.
22. Quadro L, Fattoruso O, Cosma MP, et al. Loss of heterozygosity at the RET protooncogene locus in a case of multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab. 2001;86:239-244.
23. Lips CJ, Landsvater RM, Hoppener JW, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med. 1994; 331:828-835.
24. Wells SA Jr, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg. 1994; 220:237-247.
25. Skinner MA, DeBenedetti MK, Moley JF, Norton JA, Wells SA Jr. Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. J Pediatr Surg. 1996;31:177-181.
26. Hennessy JF, Wells SA Jr, Ontjes DA, Cooper CW. A comparison of pentagastrin injection and calcium infusion as provocative agents for the detection of medullary carcinoma of the thyroid. J Clin Endocrinol Metab. 1974;39: 487-495.
27. Wells SA Jr, Baylin SB, Linehan WM, Farrell RE, Cox EB, Cooper CW. Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann Surg. 1978;188:139-141.
28. Parthemore JG, Bronzert D, Roberts G, Deftos LJ. A short calcium infusion in the diagnosis of medullary thyroid carcinoma. J Clin Endocrinol Metab. 1974;39:108-111.
29. Yoshimoto K, Tanaka C, Moritani M, et al. Infrequent detectable somatic mutations of the RET and glial cell linederived neurotrophic factor (GDNF) genes in human pituitary adenomas. Endocr J. 1999;46:199-207.
30. Urbano AG, Suarez-Penaranda JM, Dieguez C, Alvarez CV. GDNF and RET-gene expression in anterior pituitary-cell types. Endocrinology. 2000;141:1893-1896.
31. Japon MA, Urbano AG, Saez C, et al. Glial-derived neurotropic factor and RET gene expression in normal human anterior pituitary cell types and in pituitary tumors. J Clin Endocrinol Metab. 2002;87:1879-1884.